secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akili, Inc. (—)
CIK:        0001850266
Form:       8-K
Filed at:   2023-10-27T23:59:59+00:00
Accession:  0000950170-23-056008
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Akili receives Nasdaq bid price deficiency notice; 180-day cure period until Apr 2024
--------------------------------------------------------------------------------

- Nasdaq staff notified Akili on Oct 24, 2023 that bid price closed below $1.00 for 30 consecutive days from Sep 11 to Oct 23.
- Company has 180 calendar days, until April 22, 2024, to regain compliance by achieving a $1.00 closing bid price for at least 10 consecutive business days.
- If not cured by April 22, Akili may be eligible for an additional 180-day period if it meets all other Capital Market listing standards, excluding bid price.
- Company may consider a reverse stock split to regain compliance, but no decision has been made and no assurance of success.
- Listing on Nasdaq Capital Market continues normally during the cure period; delisting risk remains if deficiency not resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850266/000095017023056008/0000950170-23-056008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850266/000095017023056008/akli-20231024.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-056008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer